androstane-3,17-diol has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cookson, MS; Dhanasekaran, DN; Disch, BC; Fung, KM; Ihnat, MA; Jayaraman, M; Lai, DV; Lin, HK; Stratton, KL; Thorpe, JE; Webb, ZD; Wu, W; Xia, D; Yang, Q; Yu, Z; Zhao, L | 1 |
| Fung, KM; Lin, HK; Titus, MA; Yang, Q | 1 |
2 other study(ies) available for androstane-3,17-diol and Disease Exacerbation
| Article | Year |
|---|---|
Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Topics: Aldo-Keto Reductase Family 1 Member C3; Anabolic Agents; Androstane-3,17-diol; Cell Proliferation; Disease Progression; ErbB Receptors; Humans; Male; Prostatic Neoplasms; Receptors, GABA-A; Signal Transduction; Tumor Cells, Cultured | 2018 |
5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Topics: Androstane-3,17-diol; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoplasm; Dihydrotestosterone; Disease Progression; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Models, Biological; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Time Factors | 2008 |